

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer [ID6368]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Stakeholders raised that:

ALK mutation positive NSCLC is more common in people of Asian ethnicity and alectinib is not expected to have any differences in efficacy based on ethnicity.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The prevalence of a condition is not a protected characteristic under the Equality Act 2010 and cannot be addressed in a technology appraisal.

Where appropriate and evidence allows, the committee may consider the differential clinical- or cost-effectiveness of the technology in relevant subgroups. But this will be based on expectation of known, biological plausible mechanisms, or other clearly justified factors.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No

Approved by Associate Director (name): Jasdeep Hayre

Date: 3 March 2024